M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback